Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKesson
AstraZeneca
Express Scripts
McKinsey

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Aprepitant - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for aprepitant and what is the scope of patent protection?

Aprepitant is the generic ingredient in three branded drugs marketed by Glenmark Pharms Sa, Sandoz, Merck, Heron Theraps Inc, and Msd Merck Co, and is included in five NDAs. There are six patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Aprepitant has fifty-four patent family members in thirty-seven countries.

There are twenty-six drug master file entries for aprepitant. Four suppliers are listed for this compound.

Drug Prices for aprepitant

See drug prices for aprepitant

Recent Clinical Trials for aprepitant

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Northwell HealthPhase 1/Phase 2
Ain Shams UniversityPhase 4
CR-CSSS Champlain-Charles-Le MoynePhase 3

See all aprepitant clinical trials

Recent Litigation for aprepitant

Identify potential future generic entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.2014-04-01
LUPIN ATLANTIS HOLDINGS S.A. v. APOTEX INC.2011-03-18
MERCK & CO., INC. v. SANDOZ INC.2009-02-27

See all aprepitant litigation

Paragraph IV (Patent) Challenges for APREPITANT
Tradename Dosage Ingredient NDA Submissiondate
EMEND FOR SUSPENSION;ORAL aprepitant 207865 2016-11-23
EMEND CAPSULE;ORAL aprepitant 021549 2008-11-03

US Patents and Regulatory Information for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heron Theraps Inc CINVANTI aprepitant EMULSION;INTRAVENOUS 209296-001 Nov 9, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-002 Sep 24, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-003 Oct 12, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Heron Theraps Inc CINVANTI aprepitant EMULSION;INTRAVENOUS 209296-001 Nov 9, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003   Start Trial   Start Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003   Start Trial   Start Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006   Start Trial   Start Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003   Start Trial   Start Trial
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for aprepitant

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0748320 08C0019 France   Start Trial PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381 PA2004002,C0734381 Lithuania   Start Trial PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
0734381 3/2004 Austria   Start Trial PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0734381 PA2004002 Lithuania   Start Trial PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
0734381 SPC/GB04/011 United Kingdom   Start Trial PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKinsey
Medtronic
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.